ReviewCurrent opinion in infectious diseases2015
Clinical perspectives on echinocandin resistance among Candida species.
Review in Current opinion in infectious diseases, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 1 synthesis or guideline pooled it, 75 citations in OpenAlex.
- Pooled it
- Diverse genetic pathways drive convergent fluconazole and caspofungin resistance phenotypes in Candida albicans.PloS one · 2026Article
- ATR-FTIR spectroscopic markers indicating drug resistance in selected Candida strains.Scientific reports · 2025Article
- COProceedings of the National Academy of Sciences of the United States of America · 2025Article
- Characteristics, risk factors, and outcomes of bloodstreamThe Journal of international medical research · 2023Article
- Liposomal amphotericin B-the future.The Journal of antimicrobial chemotherapy · 2022Article
- Pan-Echinocandin ResistantJournal of fungi (Basel, Switzerland) · 2022Article
- Present scenarios and future prospects of herbal nanomedicine for antifungal therapy.Journal of drug delivery science and technology · 2022Review
- Molecular mechanisms of acquired antifungal drug resistance in principal fungal pathogens and EUCAST guidance for their laboratory detection and clinical implications.The Journal of antimicrobial chemotherapy · 2022Review
- The Caspofungin Paradoxical Effect is a Tolerant "Eagle Effect" in the Filamentous Fungal PathogenmBio · 2022Article
- [Consensus on diagnosis and treatment of invasive fungal infection in patients with severe liver disease].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2022Article
- Molecular Mechanisms of Antifungal Resistance in Mucormycosis.BioMed research international · 2022Review
- Crosstalk between the calcineurin and cell wall integrity pathways prevents chitin overexpression in Candida albicans.Journal of cell science · 2021Article
- Danish Whole-Genome-SequencedJournal of fungi (Basel, Switzerland) · 2021Article
- Monocyte human leukocyte antigen-DR but not β-D-glucan may help early diagnosing invasive Candida infection in critically ill patients.Annals of intensive care · 2021Article
- Candidemia in intensive care units over nine years at a large Italian university hospital: Comparison with other wards.PloS one · 2021Article
- Article
- Antifungal Resistance inAntibiotics (Basel, Switzerland) · 2020Review
- Review on Current Status of Echinocandins Use.Antibiotics (Basel, Switzerland) · 2020Review
- Risk factors for candidemia: a prospective matched case-control study.Critical care (London, England) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
purpose of reviewWe review and offer our clinical perspectives on the emergence of echinocandin-resistant Candida. RECENT
findingsCandida FKS gene mutations attenuate echinocandin activity, but overall mutation rates among clinical isolates remain low (Candida glabrata, ∼4%; other species, <1%). Rates are higher with prior echinocandin exposure, exceeding 50% among C. glabrata or Candida albicans isolates causing breakthrough invasive candidiasis. The median duration of prior echinocandin exposure among FKS mutant isolates is ∼100 days. The clinical usefulness of echinocandin susceptibility testing is limited by the low overall prevalence of resistance, and uncertainties surrounding testing methods and interpretation of minimum inhibitory concentrations (MICs). In single-center studies, caspofungin resistance (defined using institution-specific MIC breakpoints) was 32-53% sensitive and 75-95% specific for predicting treatment outcomes of C. glabrata invasive candidiasis; corresponding values for the presence of an FKS mutation were 35-41% and 90-98%. Results were similar using anidulafungin and micafungin MICs. Clinical data are scarce for non-C. glabrata species. SUMMARY: Echinocandins remain preferred agents against invasive Candida infections. Susceptibility testing and FKS genotypic testing do not have roles in routine clinical practice, but may be useful in newly-diagnosed patients who are echinocandin-experienced or those who have not responded to echinocandin treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.